A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens

Critical Reviews in Toxicology

Volumn 41, Issue 6, 2011, Pages 507-544

  Felter, Susan P ^a   Conolly, Rory B ^b   Bercu, Joel P ^c   Bolger, P Michael ^d   Boobis, Alan R ^e   Bos, Peter M J ^f   Carthew, Philip ^g   Doerrer, Nancy G ^h   Goodman, Jay I ⁱ   Harrouk, Wafa A ^d   Kirkland, David J ^j   Lau, Serrine S ^k   Llewellyn, G Craig ^l   Preston, R Julian ^b   Schoeny, Rita ^m   Schnatter, A Robert ⁿ   Tritscher, Angelika ^o   Van Velsen, Frans ^p   Williams, Gary M ^q  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^g UNILEVER RESEARCH   (United Kingdom)

^h ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

ⁱ MICHIGAN STATE UNIVERSITY   (United States)

^j Kirkland Consulting   (United Kingdom)

^k UNIVERSITY OF ARIZONA   (United States)

^l Kraft Foods   (United States)

^m U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

ⁿ EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^o WORLD HEALTH ORGANIZATION   (Switzerland)

^p JOHNSON AND JOHNSON   (United States)

^q NEW YORK MEDICAL COLLEGE   (United States)

more..

Author keywords

Cancer risk assessment; dose rate correction factors (DRCFs); Haber's Rule; intermittent exposure; lessthan lifetime exposure (LTL); short term exposure; threshold of toxicological concern (TTC)

Indexed keywords

1 AMINO 2,4 DIBROMOANTHRAQUINONE; 1,3 BUTADIENE; 4 NITROANISOLE; ANTHRAQUINONE DERIVATIVE; AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CONSTITUTIVE ANDROSTANE RECEPTOR; COUMARIN; DIBROMONEOPENTYL GLYCOL; DICHLOROMETHANE; DIHYDROCOUMARIN; FURAN; METHYLEUGENOL; N (2 FLUORENYL)ACETAMIDE; PENTACHLOROPHENOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROPANEDIOL DERIVATIVE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

CANCER RISK; CARCINOGENESIS; DNA REPAIR; GENETIC PREDISPOSITION; GENOTOXICITY; HUMAN; LIFESTYLE; LONG TERM EXPOSURE; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; TOXICOKINETICS;

RODENTIA;

EID: 79958785810     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2011.552063     Document Type: Review

References (199)

1. Albert RE. (1994). Carcinogen risk assessment in the U.S. Environmental Protection Agency. Crit Rev Toxicol 24:75-85. (Pubitemid 24122408)
2. Ames BN. (1973). Carcinogens are mutagens: Teir detection and classifcation. Environ Health Perspect 6:115-118.
3. Ames BN, Gold LS. (1997). The causes and prevention of cancer: Gaining perspective. Environ Health Perspect 105:865-873. (Pubitemid 27372974)
4. Andersen ME, Clewell HJ III, Gargas ML, Smith FA, Reitz RH. (1987). Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205. (Pubitemid 17019104)
5. Anderson LM, Diwan BA, Fear NT, Roman E. (2000). Critical windows of exposure for children's health: Cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect 108(Suppl 3):573-594. (Pubitemid 30466185)
6. Armitage P, Doll R. (1954).Te age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 8:1-12.
7. Balmain A, Harris CC. (2000). Carcinogenesis in mouse and human cells: Parallels and paradoxes. Carcinogenesis 21:371-377. (Pubitemid 30137922)
8. Barlow SM, Kozianowski G, Würtzen G, Schlatter J. (2001). Treshold of toxicological concern for chemical substances present in the diet. Report of a workshop, 5-6 October 1999, Paris, France. Food Chem Toxicol 39:893-905.
9. Barton HA, Cogliano VJ, Flowers L, Valcovic L, Setzer RW, Woodruf TJ. (2005). Assessing susceptibility from early-life exposure to carcinogens. Environ Health Perspect 113:1125-1133. (Pubitemid 41387648)
10. Bartsch H, Dally H, Popanda O, Risch A, Schmezer, P. (2007). Genetic risk profles for cancer susceptibility and therapy response. Recent Results Cancer Res 174(Cancer Prevent):19-36.
11. Benfenati E, Benigni R, Demarini DM, Helma C, Kirkland D, Martin TM, Mazzatorta P, Ouédraogo-Arras G, Richard AM, Schilter B, Schoonen WG, Snyder RD, Yang C. (2009). Predictive models for carcinogenicity and mutagenicity: Frameworks, state-of-the-art, and perspectives. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27:57-90.
12. Benford D, Leblanc JC, Setzer RW. (2010). Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic: Example: Afatoxin B1 (AFB1). Food Chem Toxicol 48(Suppl 1):S34-S41.
13. Benigni R, Worth A, Netzeva T, Jeliazkova N, Bossa C, Gruska A, Franke R. (2009). Structural motifs modulating the carcinogenic risk of aromatic amines. Environ Mol Mutagen 50:152-161.
14. Bercu JP, Morton SM, Deahl JT, Gombar VK, Callis CM, van Lier RBL. (2010). In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances. Regul Toxicol Pharmacol 57:300-306.
15. Berenblum I. (1974). North-Holland Research Monographs, Frontiers of Biology, Vol 34. Carcinogenesis as a biological problem. New york: Elsevier, 376 pp.
16. Birnbaum LS, Fenton SE. (2003) Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 111:389-394. (Pubitemid 36546511)
17. Bolt HM. (2003). Review. Genotoxicity: Treshold or not? Introduction of cases of industrial chemicals. Toxicol Lett 140/141:43-51. (Pubitemid 36378922)
18. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D, Farland W. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36:781-792. (Pubitemid 44800328)
19. Boobis AR, Daston GP, Preston RJ, Olin SS. (2009). Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr 49:690-707.
20. Bos PMJ, Baars B-J, van Raaiij MTM. (2004). Risk assessment of peak exposure to genotoxic carcinogens: A pragmatic approach. Toxicol Lett 151:43-50. (Pubitemid 38739026)
21. Bucher JR, Melnick RL, Hildebrandt PK. (1993) Lack of carcinogenicity in mice exposed once to high concentrations of 1,3-butadiene. J Natl Cancer Inst 85:1866-1867. (Pubitemid 23333623)
22. Butterworth BE, Bogdanfy MS. (1999). A comprehensive approach for integration of toxicity and cancer risk assessment. Regul Toxicol Pharmacol 29:23-36. (Pubitemid 29124241)
23. Calabrese EJ, Blain RB. (1999). The Single Exposure Carcinogen Database: Assessing the circumstances under which a single exposure to a carcinogen can cause cancer. Toxicol Sci 50:169-185. (Pubitemid 29407079)
24. Callis CM, Bercu JP, DeVries KM, Dow LK, Robbins DK, Varie DL. (2010). Risk assessment of genotoxic impurities in marketed compounds administered over a short-term duration: Applications to oncology products and implications for impurity control limits. Org Process Res Dev. 14:986-992.
25. Capen CC. (1997). Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol 25:39-48. (Pubitemid 27100557)
26. Carthew P, Rich KJ, Martin EA, DeMatteis F, Lim CK, Manson MM, Festing MJ, White INH, Smith LL. (1995). DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumour formation. Carcinogenesis 16:1299-1304.
27. Carthew P, Edwards RE, Nolan BM, Martin EA, Heydon RT, White INH, Tucker MJ. (2000). Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis 21:793-797. (Pubitemid 30214038)
28. Chan MK, Ocampo-Hafalla MT, Vartanian V, Jaruga P, Kirkali G, Koenig KL, Brown S, Lloyd RS, Dizdaroglu M, Teebor GW. (2009). Targeted deletion of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence of novel carcinogenic oxidative damage to DNA. DNA Repair (Amst) 8:786-794.
29. Cheeseman MA, Machuga EJ, Bailey AB. (1999). A tiered approach to threshold of regulation. Food Chem Toxicol 37:387-412. (Pubitemid 29335764)
30. Chen JJ, Kodell RL, Gaylor DW. (1988). Using the biological two-stage model to assess risk from short-term exposures. Risk Anal 8:223-230.
31. Chhabra RS, Maronpot RM, Bucher JR, Haseman JK, Toft JD, Hejtmancik MR. (1999). Toxicology and carcinogenesis studies of pentachlorophenol in rats. Toxicol Sci 48:14-20. (Pubitemid 29244416)
32. Cohen SM. (2008). Tresholds in genotoxicity and carcinogenicity: Urinary bladder carcinogenesis. Genes Environ 30:132-138.
33. Cohen SM, Klaunig J, Meek ME. (2004). Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci 78:181-186. (Pubitemid 38559665)
34. Collins JJ, Ireland B, Buckley C F, Shepperly D. (2003). Lymphohaematopoietic cancer mortality among workers with benzene exposure. Occup Environ Med 60:676-679. (Pubitemid 37094078)
35. Cramer GM, Ford RA, Hall RL. (1978). Estimation of toxic hazard-A decision tree approach. Food Cosmet Toxicol 16:255-276. (Pubitemid 9010193)
36. Crispo A, Brennan P, Jockel KH, Schafrath-Rosario A, Wichmann HE, Nyberg F, Simonato L, Merletti F, Forastiere F, Bofetta P, Darby S. (2004). The cumulative risk of lung cancer among current, ex- and never-smokers in European men. Br J Cancer 91:1280-1286. (Pubitemid 39424788)
37. Croce CM. (2008). Oncogenes and cancer. N Engl J Med 358:502-511. (Pubitemid 351185806)
38. Crump KS. (1984a). An improved procedure for low-dose carcinogenic risk assessment from animal data. J Environ Pathol Toxicol Oncol 5:339-348. (Pubitemid 15162433)
39. Crump KS. (1984b). A new method for determining allowable daily intakes. Fundam Appl Toxicol 4:854-871. (Pubitemid 15184906)
40. Crump K. (1994). Risk of benzene-induced leukemia: A sensitivity analysis of the plioflm cohort with additional follow-up and new exposure estimates. J Toxicol Environ Health 42:219-242. (Pubitemid 24197312)
41. Crump K, Allen B. (1984). Quantitative estimates of risk of leukemia from occupational exposure to benzene. OSHA Docket H-059b, Exhibit 152, Annex B. Washington, DC: US Department of Labor.
42. Crump KS, Chen C, Chiu WA, Louis TA, Portier CJ, Subramaniam RP, White PD. (2010). What role for biologically-based dose-response models in estimating low-dose risk? Environ Health Perspect 118:585-588.
43. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K. (2009). Prevention of breast cancer in postmenopausal women: Approaches to estimating and reducing risk. J Natl Cancer Inst 101:384-398.
44. Drew RT, Boorman GA, Haseman JK. (1983). The efect of age and exposure duration on cancer induction by a known carcinogen in rats, mice, and hamsters. Toxicol Appl Pharmacol 68:120-130. (Pubitemid 13128824)
45. Druckrey H. (1967). Quantitative aspects in chemical carcinogenesis. In: Truhaut R, ed. Potential Carcinogenic Hazards from Drugs. UICC Monograph Series, Vol. 7. New York: Springer-Verlag, 60-78.
46. Druckrey H, Lange A. (1972). Carcinogenicity of azoxymethane dependent on age in BD rats. Fed Proc 31:1482-1484.
47. Druckrey H, Schildbach A, Schmaehld D, Preussmann R, Ivankovic S. (1963). Quantitative Analyse der carcinogenen Wirkung von Diäthylnitrosamin. [Quantitative analysis of the carcinogenic efect of diethylnitrosamine]. Arzneimittelforschung 13:841-851.
48. Druckrey H, Preussmann R, Ivankovic S, Schmidt CH, So BT, Tomas C. (1965). Carcinogene wirkung von azoäthan und azoxyäthan an ratten. [Carcinogenic action of azoethane and azoxyethane in rats]. Z Krebsforsch 67:31-45.
49. Druckrey H, Preussmann R, Matzkies F, Ivankovic S. (1966). Carcinogene wirkung von 1,2-diäthylhydrazin an ratten. [Carcinogenic action of 1,2-diethylhydrazine in rats]. Naturwissenschaften 53:557-558.
50. Druckrey H, Kruse H, Preussmann R. (1968). Propanesultone, a potent carcinogen. Naturwissenschaften 55:449.
51. Druckrey H, Stekar J, Hünig S. (1973). Carcinogene wirkung von athoxy-diazenium-salzen (O-athyl-dialkylnitrosimmonium-salzen) an ratten. [Carcinogenicity of ethoxydiazenium-salts (O-ethyl-dialkylnitrosimmonium salts in rats.] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 80:17-26.
52. EFSA. (2003). Opinion of the Scientifc Panel on Plant Protection Products and Teir Residues (PPR) on a request from the Commission related to the evaluation of mepanipyrim in the context of Council Directive 91/414/EC. European Food Safety Authority. EFSA J 4:1-14.
53. EFSA. (2005). Opinion of the Scientifc Committee on a request from EFSA related to A Harmonised Approach for Risk Assessment of Substances Which are Both Genotoxic and Carcinogenic. European Food Safety Authority. Available at: http://www.efsa.europa.eu/ en/scdocs/doc/282.pdf. Accessed 1 June 2010.
54. EMA. (2006). Position Paper on the Limits of Genotoxic Impurities. European Medicines Agency. EMA/CHMP/QWP/251344/2006.
55. EMA. (2009). Questions & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities. European Medicines Agency, CPMP, Revision 2.
56. Esteller M. (2007). Cancer epigenomics: DNA methylomes and histone-modifcation maps. Nat Rev Genet 8:286-298. (Pubitemid 46439286)
57. Fenton SE, Davis CC. (2002). Atrazine exposure in utero increases dimethylbenz-a-anthracene-induced mammary tumor incidence in Long Evans ofspring. Toxicol Sci 66:185.
58. The Toxicologist, Abstracts of the 41st Annual Meeting of the Society of Toxicology. (Abstract 903).
59. Fiori JM, Meyerhof RD. (2002). Extending the threshold of regulation concept: De minimis limits for carcinogens and mutagens. Regul Toxicol Pharmacol 35:209-216. (Pubitemid 34664921)
60. Flammang TJ, Von Tungeln LS, Kadlubar FF, Fu PP. (1997). Neonatal mouse assay for tumorigenicity: Alternative to the chronic rodent bioassay. Regul Toxicol Pharmacol 26:230-240. (Pubitemid 27494297)
61. Forsberg J-G, Kalland T. (1981). Neonatal estrogen treatment and epithelial abnormalities in the cervicovaginal epithelium of adult mice. Cancer Res 41:721-734. (Pubitemid 11179423)
62. Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Håkanson R, Olbe L, Solcia E, Walsh JH, Wolfe MM. (1995). Efects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 40(Suppl 2):50S-62S.
63. Fujii, K. (1991). Evaluation of the newborn mouse model for chemical tumorigenesis. Carcinogenesis 12:1409-1415.
64. Fukushima S, Kakehashi A, Wei M, Wanibuchi H. (2009). Existence of a threshold for the genotoxic carcinogens: Evidence from mechanism-based carcinogenicity studies. Genes Environ 31:33-36.
65. Fung VA, Barrett JC, Huf J. (1995). The carcinogenesis bioassay in perspective: Application in identifying human cancer hazards. Environ Health Perspect 103:680-683.
66. Gaylor DW. (1988). Risk assessment: Short-term exposure at various ages. Basic Life Sci 43:173-176.
67. Gaylor DW. (2000). The use of Haber's Law in standard setting and risk assessment. Toxicology 149:17-19. (Pubitemid 30645783)
68. Gaylor DW, Gold LS. (1995). Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. Regul Toxicol Pharmacol 22:57-63.
69. Gaylor DW, Gold LS. (1998). Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose. Regul Toxicol Pharmacol 28:222-225. (Pubitemid 29096163)
70. Gaylor DW, Chen JJ, Sheehan DM. (1993). Uncertainty in cancer risk estimates. Risk Anal 13:149-154. (Pubitemid 23143994)
71. Gold LS, Sawyer CB, Magaw R, Backman GM, de Veciana M, Levinson R, Hooper NK, Havender WR, Bernstein L, Peto R. (1984). A carcinogenic potency database of the standardized results of animal bioassays. Environ Health Perspect 58:9-319. (Pubitemid 15134228)
72. Gold LS, Slone TH, Manley NB, Garfnkel GB, Hudes ES, Rohrbach L, Ames BN. (1991). The Carcinogenic Potency Database: Analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/ National Toxicology Program. Environ Health Perspect 96:11-15.
73. Gold LS, Slone TH, Stern BR, Manley NB, Ames BN. (1992). Rodent carcinogens: Setting priorities. Science 258:261-265.
74. Gold LS, Manley NB, Slone TH, Rohrbach L. (1999). Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature iN 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. Environ Health Perspect 107(Suppl 4):527-600.
75. Gold LS, Manley NB, Slone TH, Rohrbach L, Garfnkel GB. (2005). Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program iN 1997-1998. Toxicol Sci 85:747-808. (Pubitemid 40846856)
76. Goodman JI, Watson RE. (2002). Altered DNA methylation: A secondary mechanism involved in carcinogenesis. Ann Rev Pharmacol Toxicol 42:501-525. (Pubitemid 34160534)
77. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. (1993). Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-24. (Pubitemid 23267689)
78. Haber F. (1924). Zur Geschichte des gaskrieges. In: Fünf Vorträge aus den Fahren 1920-1923. Berlin: Verlag von Fulius Springer, 23-29.
79. Halmes NC, Roberts SM, Tolson JK, Portier CJ. (2000). Reevaluating cancer risk estimates for short-term exposure scenarios. Toxicol Sci 58:32-42.
80. Hakanson R, Sundler F. (1990). Proposed mechanism of induction of gastric carcinoids: The gastrin hypothesis. Eur J Clin Invest 20(Suppl 1):S65-S71.
81. Hard GC. (1998). Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environ Health Perspect 106:427-436. (Pubitemid 28470157)
82. Health Canada. (1996). Health-Based Tolerable Daily Intakes/ Concentrations and Tumorigenic Doses/Concentrations for PrioritySubstances. Ottawa, Ontario, Canada: Environmental Health Directorate, Health Protection Branch, Health Canada. Available at: http://www.hc-sc.gc.ca/ewh-semt/pubs/ contaminants/hbct-jact/index-eng.php. Accessed 1 June 2010.
83. Hehir RM, McNamara BP, McLaughlin J, Willigan DA, Bierbower G, Hardisty JF. (1981). Cancer induction following single and multiple exposures to a constant amount of vinyl chloride monomer. Environ Health Perspect 41:63-72. (Pubitemid 12107938)
84. Holladay SD, Smialowicz RJ. (2000). Development of the murine and human immune system: Diferential efects of immunotoxicants depend on time of exposure. Environ Health Perspect 108(Suppl3):463-473. (Pubitemid 30466174)
85. Holsapple MP, West LJ, Landreth KS. (2003). Species comparison of anatomical and functional immune system development. Birth Defects Res B Dev Reprod Toxicol 68:321-334. (Pubitemid 37238421)
86. Hsieh P, Yamane K. (2008). DNA mismatch repair: Molecular mechanism, cancer, and ageing. Mech Ageing Dev 129:391-407.
87. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. (2010). Calories and carcinogenesis: Lessons learned from 30 years of calorie restriction research. Carcinogenesis 31:83-89.
88. IARC. (2003). Predictive value of rodent forestomach and gastric neuroendocrine tumours in evaluating carcinogenic risks to humans. Summary Report, IARC Technical Publication No. 39. Lyon, France: International Agency for Research on Cancer, 7-14.
89. ICH. (2006a). Q3A(R2): Impurities in New Drug Substances. Geneva, Switzerland: International Conference on Harmonisation. Available at: http://www.ich.org/LOB/media/MEDIA422.pdf. Accessed 1 June 2010.
90. ICH. (2006b). Q3B(R2): Impurities in New Drug Products. Geneva, Switzerland: International Conference on Harmonisation. Available at: http://www.ich.org/LOB/media/MEDIA421.pdf. Accessed 1 June 2010.
91. ICRP. (2007). The 2007 Recommendations of the International Commission on Radiological Protection. International Commission on Radiological Protection. Ann ICRP 37:2-4.
92. Infante P F, Wagoner JK, Sprince NL. (1980). Mortality patterns from lung cancer and nonneoplastic respiratory disease among white males in the Beryllium Case Registry. Environ Res 21:35-43. (Pubitemid 10111203)
93. Jacobson-Kram D, Jacobs A. (2005). Use of genotoxicity data to support clinical trials or positive genetox fndings on a candidate pharmaceutical or impurity. now what? Int J Toxicol 24:129-134. (Pubitemid 40993359)
94. Jefrey AM, Iatropoulos MJ, Williams GM. (2006). Nasal cytotoxicity and carcinogenic activities of systemically distributed organic chemicals. Toxicol Pathol 34:827-852. (Pubitemid 46011138)
95. Kamendulis LM, Klaunig JE. (2008). Chemical carcinogenesis. In: Klaassen CD, ed. Casarett and Doull's Toxicology, the Basic Science of Poisons. 7th ed. New York: McGraw Hill Medical, 329-380.
96. Kari FW, Foley JF, Seilkop SK, Maronpot RR, Anderson MW. (1993). Efect of varying exposure regimens on methylene chloride-induced lung and liver tumors in female B6C3F1 mice. Carcinogenesis 14:819-826. (Pubitemid 23169132)
97. Kirsch-Volders M, Gonzalez L, Carmichael P, Kirkland D. (2009). Risk assessment of genotoxic mutagens with thresholds: A brief introduction. Mutat Res 678:72-75.
98. Kodell RL, Gaylor DW, Chen JJ. (1987). Using average lifetime dose rate for intermittent exposures to carcinogens. Risk Anal 7:339-345.
99. Koehle C, Schwarz M, Bock K. (2008). Promotion of hepatocarcinogenesis in humans and animal models. Arch Toxicol 82:623-631.
100. Krestinina LY, Davis F, Ostroumova E, Epifanova S, Degleva M, Preston D, Akleyev A. (2007). Solid cancer incidence and low-dose-rate radiation exposures in the Techa River cohort: 1956-2002. Int J Epidemiol 36:1038-1046. (Pubitemid 350018548)
101. Kroes R, Renwick AG, Cheeseman M, Kleiner K, Mangelsdorf I, Piersma A, Schilter B, Schlatter J, van Schothorst F, Vos JG, Wurtzen G. (2004). Structure-based thresholds of toxicological concern (TTC): Guidance for application to substances present at low levels in the diet. Food Chem Toxicol 42:65-83. (Pubitemid 37421327)
102. Kroes R, Renwick AG, Feron V, Galli CL, Gibney M, Greim H, Guy RH, Lhuguenot JC, van de Sandt JJ. (2007). Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. Food Chem Toxicol 45:2533-2562. (Pubitemid 47610800)
103. Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I, Tokuoka S. (2003). Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 160:707-717. (Pubitemid 37521714)
104. Larsen E, Meza TJ, Kleppa L, Klungland A. (2007). Organ and cell specifcity of base excision repair mutants in mice. Mutat Res 614:56-68. (Pubitemid 44920331)
105. Levy PS, Roth HD, Deubner DC. (2007). Exposure to beryllium and occurrence of lung cancer: A reexamination of fndings from a nested case-control study. J Occup Environ Med 49:96-101. (Pubitemid 46095595)
106. Lipinski CA. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249. (Pubitemid 32239479)
107. Littlefeld NA, Farmer JH, Gaylor DW. (1979) Efects of dose and time in a long-term, low dose carcinogenicity study. J Environ Pathol Toxicol 3:17-34.
108. Lock EA, Reed CJ. (2006). Trichloroethylene: Mechanisms of renal toxicity and renal cancer and relevance to risk assessment. Toxicol Sci 91:313-331. (Pubitemid 43827285)
109. Lopez J, Percharde M, Coley HM, Webb A, Crook T. (2009). The context and potential of epigenetics in oncology. Br J Cancer 100:571-577.
110. Lutz WK. (2009). The Viracept (nelfnavir)-ethyl methanesulfonate case. A threshold risk assessment for human exposure to a genotoxic drug contamination? Toxicol Lett 190:239-242.
111. MacDonald JS, Scribner HE. (1999). The maximum tolerated dose and secondary mechanisms of carcinogenesis. In: Kitchin KT, ed. Carcinogenicity Testing, Predicting, and Interpreting Chemical Efects. New York: Marcel-Dekker, 125-144.
112. Mancuso T F. (1980). Mortality study of beryllium industry workers' occupational lung cancer. Environ Res 21:48-55. (Pubitemid 10111205)
113. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorf LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. (2009). Finding the missing heritability of complex diseases. Nature 46:747-753.
114. Marron M, Bofetta P, Zhang Z-F, Zaridze D, Wunsch-Filho V, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Smith E, Schwartz SM, Rudnai P, Purdue MP, Olshan AF, Eluf-Neto J, Muscat J, Morgenstern H, Menezes A, McClean M, Matos E, Mates IN, Lissowska J, Levi F, Lazarus P, La Vecchia C, Koifman S, Kelsey K, Herrero R, Hayes RB, Franceschi S, Fernandez L, Fabianova E, Daudt AW, Dal Maso L, Curado MP, Cadoni G, Chen C, Castellsague X, Boccia S, Benhamou S, Ferro G, Berthiller J, Brennan P, Møller H, Hashibe M. (2010). Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol 39:182-196.
115. Martínez ME. (2005). Primary prevention of colorectal cancer: Lifestyle, nutrition, exercise. Recent results. Cancer Res 166:177-211.
116. McClain RM, Keller D, Casciano D, Fu P, MacDonald J, Popp J, Sagartz J. (2001). Neonatal mouse model: Review of methods and results. Toxicol Pathol 29:128-137.
117. McConnell EE. (1992). Comparative response in carcinogenesis bioassay as a function of age at frst exposure. In: Guzelian P, Henry CJ, Olin SS, eds. Similarities and Diference Between Children and Adults: Implications for Risk Assessment. Washington, DC: ILSI Press, 66-78.
118. McGregor D, Bolt H, Cogliano V, Richter-Reichhelm H-B. (2006). Formaldehyde and glutaraldehyde and nasal cytotoxicity: Case study within the context of thE 2006 IPCS human framework for the analysis of a cancer mode of action for humans. Crit Rev Toxicol 36:821-835. (Pubitemid 44800331)
119. Meek M, Bucher J, Cohen S, Dellarco V, Hill R, Lehman-McKeeman L, Longfellow D, Pastoor T, Seed J, Patton D. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33:591-653. (Pubitemid 38040084)
120. Meek ME, Renwick A, Ohanian E, Dourson M, Lake B, Naumann BD, Vu V; International Programme on Chemical Safety. (2002). Guidelines for application of chemical-specifc adjustment factors in dose/concentration-response assessment. Toxicology 181-182:115-120. (Pubitemid 36015683)
121. Miller FJ, Schlosser PM, Janszen DB. (2000). Haber's Rule: A special case in a family of curves relating concentration and duration of exposure to a fxed level of response for a given endpoint. Toxicol 149:21-34. (Pubitemid 30645784)
122. Miller MD, Marty MA, Arcus A, Brown J, Morry D, Sandy M. (2002). Diferences between children and adults: Implications for risk assessment at California EPA. Int J Toxicology 21:403-418. (Pubitemid 35332440)
123. Montandon F, Williams GM. (1994). Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch Toxicol 68:272-275. (Pubitemid 24133455)
124. Muirhead CR, O'Hagan JA, Haylock RG, Philippson MA, Wilcock T, Berridge GL, Zhang W. (2009). Mortality and cancer incidence following occupational radiation exposure: Tird analysis of the National Registry for Radiation Workers. Br J Cancer 100:206-212.
125. Müller L, Gocke E, Lavé T, Pfster T. (2009). Ethyl methanesulfonate toxicity in Viracept-A comprehensive human risk assessment based on threshold data for genotoxicity. Toxicol Lett 190:317-329.
126. Müller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels C, DeGeorge J, De Knaep AG, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CD, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK, O'Donovan MR, Smith MD, Vudathala G, Yotti L. (2006). A rationale for determining, testing, and controlling specifc impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxicol Pharmacol 44:198-211.
127. Munro IC, Ford RA, Kennepohl E, Sprenger JG. (1996). Correlation of structural class with no-observed-efect levels: A proposal for establishing a threshold of concern. Food Chem Toxicol 34:829-867. (Pubitemid 26420127)
128. Munro IC, Kennepohl E, Kroes R. (1999). A procedure for the safety evaluation of favouring substances. Joint FAO/WHO Expert Committee on Food Additives. Food Chem Toxicol 37:207-232. (Pubitemid 29236047)
129. Murdoch DJ, Krewski D. (1988). Carcinogenic risk assessment with time-dependent exposure patterns. Risk Anal 8:521-530. (Pubitemid 19037085)
130. Murdoch DJ, Krewski D, Wargo J. (1992). Cancer risk assessment with intermittent exposure. Risk Anal 12:569-577. (Pubitemid 23050544)
131. Nordstrand LM, Ringvoll J, Larsen E, Klungland A. (2007). Genome instability and DNA damage accumulation in gene-targeted mice. Neuroscience 145:1309-1317. (Pubitemid 46602740)
132. NRC. (1983). Risk Assessment in the Federal Government: Managing the Process. Washington, DC: National Research Council, The National Academies Press.
133. NRC. (1993). Pesticides in the Diets of Infants and Children. Washington, DC: National Research Council, The National Academies Press.
134. NRC. (2001). Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals. Washington, DC: National Research Council, The National Academies Press.
135. NRC. (2006). Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: National Research Council, The National Academies Press.
136. NRC. (2009). Science and Decisions: Advancing Risk Assessment. Washington, DC: National Research Council, The National Academies Press.
137. NTP. (1993a). Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CAS No. 106-99-0) in B6C3F1 Mice (Inhalation Studies). NTP Technical Report Series, No. 434. Research Triangle Park, NC: National Toxicology Program.
138. NTP. (1993b). Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344 Rats and B6C3F1 Mice (Gavage Studies). NTP Technical Report Series, No. 422. Research Triangle Park, NC: National Toxicology Program.
139. NTP. (1993c). Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344 Rats and B6C3F1 Mice (Gavage Studies). NTP Technical Report Series, No. 423. Research Triangle Park, NC: National Toxicology Program.
140. NTP. (1993d). Toxicology and Carcinogenesis Studies of Furan (CAS No. 110-00-9) in F344 Rats and B6C3F1 Mice (Gavage Studies). NTP Technical Report Series, No. 402. Research Triangle Park, NC: National Toxicology Program.
141. NTP. (1993e). Toxicology and Carcinogenesis Studies of o-Nitroanisole (CAS) No. 91-23-6) in F344 Rats and B6C3F1 Mice (Feed Studies). NTP Technical Report Series, No. 416. Research Triangle Park, NC: National Toxicology Program.
142. NTP. (1996a). Toxicology and Carcinogenesis Studies of 1-Amino-2,4-dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies). NTP Technical Report Series, No. 383. Research Triangle Park, NC: National Toxicology Program.
143. NTP. (1996b). Toxicology and Carcinogenesis Studies of 2,2-bis(Bromomethyl)-1,3-propanediol (FR-1138®) (CAS Mp/ 3296-90-0) in F344/N Rats and B6C3F1 Mice (Feed Studies). NTP Technical Report Series, No. 452. Research Triangle Park, NC: National Toxicology Program.
144. NTP (1997). Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine in F344/N rats and B6C3F1 Mice (Gavage Studies). NTP Technical Report, Series No. 457. Research Triangle Park, NC: National Toxicology Program.
145. NTP (1999). Toxicology and Carcinogenesis Studies of Pentachlorophenol in F344/N Rats (Feed Studies). NTP Toxicity Report, Series No. 483. Research Triangle Park, NC: National Toxicology Program.
146. NTP (2000). Toxicology and Carcinogenesis Studies of Methyleugenol in F344/N Rats and B6C3F1 Mice (Gavage Studies). NTP Technical Report, Series No. 491. Research Triangle Park, NC: National Toxicology Program.
147. Parodi S, Malacarne D, Romano P, Taningher M. (1991). Are genotoxic carcinogens more potent than nongenotoxic carcinogens? Environ Health Perspect 95:199-204.
148. Patlewicz G, Jeliazkova N, Saford RJ, Worth AP, Aleksiev B. (2008). An evaluation of the implementation of the Cramer classifcation scheme in the ToxTree software. SAR QSAR Environ Res 19:495-524.
149. Paustenbach DJ, Price PS, Ollison W, Blank C, Jernigan JD, Bass RD, Peterson HD. (1992). Reevaluation of benzene exposure for the plioflm (rubber worker) cohort (1936-1976). J Toxicol Environ Health 36:177-231.
150. Peto R, Pike MC, Bernstein L, Gold LS, Ames BN. (1984). The TD50: A proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. Environ Health Perspect 58:1-8. (Pubitemid 15134227)
151. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. (2000). Smoking, smoking cessation, and lung cancer in the U.K. since 1950: Combination of national statistics with two case-control studies. BMJ 321:323-329. (Pubitemid 30496873)
152. Ponder BA. (2001). Cancer genetics. Nature 411:336-341. (Pubitemid 32467042)
153. Poynter D, Pick CR, Harcourt RA, Selway SA, Ainge G, Harman IW, Spurling NW, Fluck PA, Cook JL. (1985). Association of long lasting unsurmountable histamine H blockade and gastric carcinoid tumours in the rat. Gut 26:1284-1295. (Pubitemid 16134450)
154. Preston RJ. (1992). A consideration of the mechanisms of induction of mutations in mammalian cells by low doses and dose rates of ionizing radiation. In: Nygaard O, Sinclair, W, Lett J, eds. Advances in Radiation Biology. Vol. 16. Maryland Heights, MO: Academic Press, 125-135.
155. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. (2007). Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 168:1-64. (Pubitemid 351292925)
156. Rangarajan A, Weinberg RA. (2003). Comparative biology of mouse versus human cells: Modeling human cancer in mice. Nat Rev Cancer 3:952-959. (Pubitemid 37500180)
157. Richardson DB. (2008). Temporal variation in the association between benzene and leukemia mortality. Environ Health Perspect 116:370-374. (Pubitemid 351395606)
158. Richardson DB, Terschüren C, Pohlabeln H, Jöckel KH, Hofmann W. (2008). Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control 19:43-50.
159. Rozman KK, Doull J. (2000a). Dose and time as variables of toxicity. Toxicology 144:169-178. (Pubitemid 30201634)
160. Rozman KK, Doull J. (2000b). Using Haber's Law to defne the margin of exposure. Toxicology 149:1-2. (Pubitemid 30645782)
161. Rozman KK, Doull J. (2001). The role of time as a quantifable variable of toxicity and the experimental conditions when Haber's C×T product can be observed: Implications for therapeutics. J Pharmacol Exp Ter 296:663-668. (Pubitemid 32187332)
162. Rulis AM. (1986). De minimis and the threshold of regulation. In: Felix CW, ed. Food Protection Technology. Current and Projected Technologies for Food Protection. Recommendation for Implementation. Proceedings of the 1986 Conference for Food Protection. Chelsea, MI: Lewis Publishers, 29-37.
163. Sanderson WT, Ward EM, Steenland K, Petersen MR. (2001). Lung cancer case-control study of beryllium workers. Am J Indust Med 39:133-144. (Pubitemid 32147531)
164. Sanner T, Dybing E. (2005). Comparison of carcinogenic and in vivo genotoxic potency estimates. Basic Clin Pharmacol Toxicol 96:131-139. (Pubitemid 40320617)
165. Sawyer C, Peto R, BernsteinL, Pike MC. (1984). Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. Biometrics 40:27-40.
166. Scheuplein R, Charnley G, Dourson M. (2002). Diferential sensitivity of children and adults to chemical toxicity. I. Biological basis. Regul Toxicol Pharmacol 35:429-447. (Pubitemid 35026242)
167. Schubauer-Berigan MK, Deddens JA, Steenland K, Sanderson WT, Petersen MR. (2008). Adjustment for temporal confounders in a reanalysis of a case-control study of beryllium and lung cancer. Occup Environ Med 65:379-383. (Pubitemid 351775797)
168. Seed J, Carney EW, Corley RA, Crofton KM, DeSesso JM, Foster PM, Kavlock R, Kimmel G, Klaunig J, Meek ME, Preston RJ, Slikker W Jr, Tabacova S, Williams GM, Wiltse J, Zoeller RT, Fenner-Crisp P, Patton DE. (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol 35:664-672.
169. Seitz HK, Becker P. (2007). Alcohol metabolism and cancer risk. Alcohol Res Health 30:38-41, 44-47.
170. Slikker W Jr, Andersen ME, Bogdanfy MS, Bus JS, Cohen SD, Conolly RB, David RM, Doerrer NG, Dorman DC, Gaylor DW, Hattis D, Rogers JM, Setzer RW, Swenberg JA, Wallace K. (2004a). Dose-dependent transitions in mechanisms of toxicity: Case studies. Toxicol Appl Pharmacol 201:226-294. (Pubitemid 39593626)
171. Slikker W Jr, Mei N, Chen T. (2004b). N-Ethyl-N-nitrosourea (ENU) increased brain mutations in prenatal and neonatal mice but not in the adults. Toxicol Sci 81:112-120. (Pubitemid 39199869)
172. Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, Fenner-Crisp P, Grant D, Hartley M, Knaap A, Kroese D, Mangelsdorf I, Meek E, Rice JM, Younes M. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol 34:146-152. (Pubitemid 33022326)
173. ten Berge WF, Zwart A, Appelman LM. (1986). Concentration-time mortality response relationship for irritant and systemically acting vapours and gases. J Hazard Mater 13:301-309. (Pubitemid 16041334)
174. Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R. (2008). Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: A clinical review. Acta Obstet Gynecol Scand 87:1101-1113.
175. Travis CC, Saulsbury AW, Pack SA. (1990). Prediction of cancer potency using a battery of mutation and toxicity data. Mutagenesis 5:213-219. (Pubitemid 20329937)
176. UK Committee on Carcinogenicity (2004). Guidance on a Strategy for the Risk Assessment of Chemical Carcinogens. London: UK, Department of Health.
177. UK Committee on Carcinogenicity. (2005). Single/short term exposure to carcinogens. Available at: http://www.iacoc.org.uk/papers/ documents/cc0619.pdf. Accessed 1 June 2010.
178. Ullrich RL, Jernigan MC, Cosgrove GE, Satterfeld LC, Bowles ND, Storer JB. (1976). The infuence of dose and dose rate on the incidence of neoplastic disease in RFM mice after neutron irradiation. Radiat Res 68:115-131.
179. US EPA. (1976). Interim procedures and guidelines for health risk and economic impact assessments of suspected carcinogens. Washington, DC: US Environmental Protection Agency, Ofce of the Administrator.
180. US EPA. (1986). Guidelines for Carcinogen Risk Assessment. Washington, DC: US Environmental Protection Agency, Risk Assessment Forum.
181. US EPA. (2005a). Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001F. Washington, DC: Risk Assessment Forum. Available at: http://www.epa.gov/cancerguidelines/. Accessed 1 June 2010.
182. US EPA. (2005b). Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens. EPA/630/R-03/003F. Washington, DC: Risk Assessment Forum. Available at: http:// www.epa.gov/cancerguidelines/sup- guidance-early-life-exp-carcinogens.htm. Accessed 1 June 2010.
183. US FDA. (1995). Food additives: Treshold of regulation for substances used in food-contact articles, fnal rule. 60 Fed Reg 36581-36596 and 21 CFR Parts 5, 25, 170, 171 and 174. Washington, DC: US Food and Drug Administration.
184. US FDA. (2008). Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. Silver Spring, MD: US Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf. Accessed 1 September 2010.
185. Venkatapathy R, Wang CY, Bruce RM, Moudgal C. (2009). Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals I. Alternative toxicity measures as an estimator of carcinogenic potency. Toxicol Appl Pharmacol 234:209-221.
186. Verhagen H, Feron VJ, Van Vliet PW. (1994). Risk assessment of peak exposure to genotoxic carcinogens. No. A94/04. The Hague, Netherlands: Health Council of The Netherlands.
187. Vogelstein B, Kinzler KW. (2004). Cancer genes and the pathways they control. Nat Med 10:789-799. (Pubitemid 39070849)
188. Wakai K, Seki N, Tamakoshi A, Kondo T, Nishino Y, Ito Y, Suzuki K, Ozasa K, Watanabe Y, Ohno Y, JACC Study Group. (2001). Japan Collaborative Cohort Study. Decrease in risk of lung cancer death in males after smoking cessation by age at quitting: Findings from the JACC study. Jpn J Cancer Res 92:821-828. (Pubitemid 32894090)
189. Weisburger EK. (1983). History of the bioassay program of the National Cancer Institute. Prog Exp Tumor Res 26:187-201.
190. WHO. (2005). Chemical-specific adjustment factors for interspecies differences and human variability: Guidance document for use of data in dose/concentration-response assessment. WHO IPCS Harmonization Project Document No. 2. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/publications/2005/9241546786-eng.pdf. Accessed 7 April 2010.
191. WHO (2006). Evaluation of Certain Food Contaminants (Sixty-Fourth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 930. Geneva, Switzerland: World Health Organization.
192. WHO. (2007). Harmonization Project Document No. 4: Part 1: IPCS Framework for Analysing the Relevance of a Cancer Mode of Action for Humans and Case Studies. Part 2: IPCS Framework for Analysing the Relevance of a Non-Cancer Mode of Action for Humans. Available at: http://www.who.int/ipcs/methods/ harmonization/areas/cancer-mode.pdf. Accessed 1 June 2010.
193. Williams GM, Iatropoulos MJ. (2002). Alteration of liver cell function and proliferation: Diferentiation between adaptation and toxicity. Toxicol Pathol 30:41-53. (Pubitemid 34201768)
194. Williams GM, Iatropoulos MJ. (2009). Evaluation of potential human carcinogenicity of the synthetic monomer ethyl acrylate. Reg Toxicol Pharmacol 53:6-15.
195. Williams GM, Iatropoulos MJ, Djordjevic M V, Kaltenberg OP. (1993). The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317. (Pubitemid 23143415)
196. Williams GM, Iatropoulos MJ, Jefrey AM. (2000). Mechanistic basis for nonlinearities and thresholds in rat liver carcinogenesis by the DNA-reactive carcinogens 2-acetylaminofuorene and diethylnitrosamine. Toxicol Pathol 28:388-395. (Pubitemid 30394813)
197. Williams GM, Iatropoulos MJ, Jefrey AM (2004). Tresholds for the efects of 2-acetylaminofuorene in rat liver. Toxicol Pathol 32:85-91. (Pubitemid 38993917)
198. Wu S, Blackburn K, Amburgey J, Jaworska J, Federle T. (2010). A framework for using structural, reactivity, metabolic and physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological assessments. Regul Toxicol Pharmacol 56:67-81.
199. Yonekura S, Nakamura N, Yonei S, Zhang-Akiyama QM (2009). Generation, biological consequences and repair mechanisms of cytosine deamination in DNA. J Radiat Res (Tokyo) 50:19-26.